Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia
Status:
Withdrawn
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Vaccines may help the body build
an effective immune response to kill cancer cells. Giving cyclophosphamide and rituximab
together with vaccine therapy may kill more cancer cells.
PURPOSE: This randomized phase II trial is studying cyclophosphamide and rituximab followed
by two different schedules of vaccine therapy to compare how well they work in treating
patients with chronic lymphocytic leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins